Navigation Links
Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
Date:3/2/2009

latory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended September 30, 2008 filed with the SEC on Form 10-Q.

G
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech Pharmaceuticals announces time change of conference call and webcast
2. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
5. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
6. Angiotech wins before the UK House of Lords
7. Angiotech to Establish Separate Operating and Royalty Businesses
8. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
9. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
10. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
11. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... 12, 2014 /CNW/ - MaRS and Virgin Unite Canada, the ... have joined forces to support Canadian entrepreneurs tackling social and ... Founder was at the MaRS Centre to announce the new ... venture fund. This fund has $1 million in seed capital ... -based Mindset Social Innovation Foundation, founded by Alison ...
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses and ... challenges. , The global synthetic biology market is ... Scientific, Inc. (U.S.), DuPont (U.S.), and Royal DSM ... ~65% of the total synthetic biology market. ... @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher Scientific, ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3
... 13 Nektar Therapeutics,(Nasdaq: NKTR ) announced ... clinical,trial of NKTR-102 in platinum-resistant ovarian cancer. Regulatory ... in two additional,trials: a randomized Phase 2 study to ... the KRAS gene mutation, and a,Phase 2 study in ...
... /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company ... early detection of diseases and personalized health management, ... # 7,473,528 entitled "Method for the detection of ... patent protects the Company,s discovery of a blood ...
... the healthcare industry creates growth opportunities for healthcare ... 13 The credit crisis and the global ... in the Healthcare industry in 2009. Healthcare in ... as the developed countries.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Dr. Louis ...
Cached Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform 22009 is Healthy for Asia 22009 is Healthy for Asia 3
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency ... to detect and prevent counterfeit microcircuits from entering ... agency started performing an in-house microcircuit anti-counterfeit initiative ... authenticity of purchased microcircuits while increasing their reliability ... measures will be conducted at DLA,s Electronics Product ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... Like coal-mine canaries, fish DNA can serve as a ... pollution--or pollution clean-up. That's one of the conclusions of ... Research Institute (PNRI), Woods Hole Oceanographic Institution, the University ... Technology (NIST). , Research over the past several years ...
... Brookhaven National Laboratory, the New York Structural Biology ... atomic crystal structure and functional mechanism of an ... as drugs, industrial chemicals, and toxic compounds from ... help scientists understand how these compounds are eliminated ...
... designed to build scientific understanding of fruit genes ... are created. , Researchers at New Zealand-based life ... science of gene discovery to such a degree ... create the individual flavours and fragrances found in ...
Cached Biology News:Precision biochemistry tracks DNA damage in fish 2Scientists take 'snapshots' of enzyme action 2Science captures the essence of fruit 2Science captures the essence of fruit 3
ID clarifier: platform...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
... Tetrad 2 thermal cycler accommodates a ... heat-pump assemblies), which hold different types ... computer drives an advanced graphical interface ... lid temperatures. Peltier heat pumps, built ...
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
Biology Products: